Abstract | BACKGROUND & AIMS: METHODS: RESULTS: In population 1, clinical response rates for the combined groups given ustekinumab and placebo were 53% and 30% (P = .02), respectively at weeks 4 and 6, and 49% and 40% (P = .34), respectively at week 8. In a subgroup of 49 patients who were previously given infliximab (neither primary nor secondary nonresponders), clinical response to ustekinumab was significantly greater than the group given placebo (P < .05) through week 8. In population 2, the clinical responses at week 8 to subcutaneous and intravenous ustekinumab were 43% and 54%, respectively. There was no increase in the number of adverse or serious adverse events in patients given ustekinumab through week 8 compared with placebo. CONCLUSIONS:
|
Authors | William J Sandborn, Brian G Feagan, Richard N Fedorak, Ellen Scherl, Mark R Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts, Ustekinumab Crohn's Disease Study Group |
Journal | Gastroenterology
(Gastroenterology)
Vol. 135
Issue 4
Pg. 1130-41
(Oct 2008)
ISSN: 1528-0012 [Electronic] United States |
PMID | 18706417
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Immunosuppressive Agents
- Interleukin-23
- Interleukin-12
- Ustekinumab
|
Topics |
- Adult
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Humanized
- Crohn Disease
(drug therapy, immunology)
- Cross-Over Studies
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects)
- Interleukin-12
(antagonists & inhibitors, immunology)
- Interleukin-23
(antagonists & inhibitors, immunology)
- Male
- Middle Aged
- Severity of Illness Index
- Treatment Outcome
- Ustekinumab
|